Physician profile
Tarun Chugh
NPI 1568695203
$2,430.13
in general payments reported to CMS, 2019-2025
27 companies · $574 in 2025
The $574 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.97 · 2020: $12.16 · 2021: $120 · 2022: $375 · 2023: $765 · 2024: $557 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821 · Education: $75.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.22 |
| Education | $75.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $266.27 | 2024-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $254.59 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $228.20 | 2023 | Xarelto |
| Daiichi Sankyo INC. | $203.00 | 2022-2025 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $178.53 | 2021-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $165.07 | 2022-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $106.22 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $105.53 | 2022-2024 | Acthar |
| Opko Pharmaceuticals, LLC | $104.60 | 2020-2024 | Rayaldee |
| Ardelyx, INC. | $86.58 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $85.94 | 2022-2023 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $85.38 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $83.66 | 2019-2022 | |
| Travere Therapeutics, INC. | $76.07 | 2024-2025 | Filspari |
| Calliditas Therapeutics US INC. | $62.44 | 2022-2025 | Tarpeyo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $52.79 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $49.46 | 2021-2024 | Benlysta, Jesduvroq |
| Alexion Pharmaceuticals, INC. | $40.25 | 2022-2023 | Ultomiris |
| Novo Nordisk INC | $37.08 | 2023-2025 | Ozempic |
| Renalytix Ai, INC. | $22.77 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Alnylam Pharmaceuticals INC. | $22.45 | 2024 | Amvuttra |
| Akebia Therapeutics INC | $21.83 | 2022 | |
| Shield Therapeutics INC | $20.67 | 2023 | Accrufer |
| Chiesi USA, INC. | $19.33 | 2023 | Elfabrio |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.90 | 2025 | Jynarque |
| Cormedix INC. | $17.10 | 2024 | Defencath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.42 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Chugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.